McKesson Bets $2.25 Billion More on Oncology With Precision Medicine Buy
Reuters reported that McKesson Corporation (NYSE:MCK) said it would buy privately held Precision Medicine Group in a deal valued at about $2.25 billion as part of a “years-long effort to strengthen its higher-growth businesses.” McKesson has been reshaping its portfolio by exiting non-core assets and streamlining its operations while investing in businesses such as oncology […]
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo